Zydus receives final approval from the USFDA for Memantine Hydrochloride Extended-Release Capsules

Ahmedabad, 5 August 2017

Zydus Cadila has received the final approval from the USFDA to market Memantine Hydrochloride Extended-Release Capsules in strengths of 7 mg, 14 mg, 21 mg, and 28 mg. The drug is used in the treatment of moderate to severe dementia of the Alzheimer's type and will be manufactured at the group's formulations manufacturing facility at Moraiya, Ahmedabad.

The sales of Memantine Hydrochloride Extended-Release Capsules is estimated at $1.1 billion. *Source: IMS Health, IMS National Sales Perspective Audit, MAT June 2017, extracted August 2017.*

The group now has more than 130 approvals and has so far filed over 300 ANDAs since the commencement of the filing process in FY 2003-04.

***